These cells can migrate back to the tumor site and drive secondary adaptive responses, primarily MHC-I-restricted CD8+ T cell-mediated cytotoxicity and likely antibody-dependent cellular cytotoxicity. This evidence concerns the gene CD8A and neoplasm.